Posted by: James Brophy
Pleio has retained GattiHR Industrial for their Vice President, Business Development and Partnerships search. Mike Delisle and Steve Doan will lead this search.
Pleio is the leader in patient engagement and medication adherence. Developed by a group of 7 partners from Boston and Montreal in 2005, our mission is to design, assemble, implement and assess costeffective health support systems that can deliver value to patients, their families, and those who support and need them. We build impactful relationships with patients on therapy using artfully scripted, live, non-clinical conversations and digital outreach. As a market leader in medication adherence, our multichannel approach to engagement increases patient adherence, instils key messages, and delivers voice of patient insights. Pleio’s proven platform, the GoodStart® program, drives revenue and improves quality, while reducing medical costs. Supported by millions of patients and some top 20 pharmaceutical companies across the nation, Pleio continues to instil lasting behaviour change through empathetic listening, warm yet scripted dialogue, digital support, and seamless integration with pharmacy.
Pleio, a leader in patient engagement and medication adherence services for pharmaceutical and healthcare customers, is seeking an entrepreneurial business development professional to lead efforts to forge business partnerships. Potential relationships include co-marketing (channel), distribution (patient access), data and other deal arrangements that further the Company’s strategic objectives including topline growth and scale up of its distribution network. Using data-driven decision making, the Vice President of Business Development and Partnerships will demonstrate high-level vision and pragmatism for partnering opportunities while bringing analytical rigor to the evaluation of those opportunities.
If you (or someone you know) is interested in this role, please contact us.
Be sure to include the job title and company name in the subject line.